Vaxart, Inc. Research And Development Expense

• Vaxart, Inc. showed an increase of +171.6% in Research And Development Expense from 2024 to 2025.
• This data is from Vaxart, Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
• XBRL data for this metric is available from 2009 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 19 years of available data (2009 to 2025), Vaxart, Inc.'s Research And Development Expense has grown by 1,122.4%.
• Historical annual values: Fiscal year 2025: $201.58 million | Fiscal year 2024: $74.21 million | Fiscal year 2023: $68.14 million | Fiscal year 2022: $81.05 million | Fiscal year 2021: $48.75 million | Fiscal year 2020: $19.86 million | Fiscal year 2019: $14.54 million | Fiscal year 2018: $17.28 million | Fiscal year 2017: $12.36 million | Fiscal year 2017: $28.30 million | Fiscal year 2016: $26.30 million | Fiscal year 2015: $19.80 million | Fiscal year 2014: $17.50 million | Fiscal year 2013: $19.90 million | Fiscal year 2012: $24.10 million | Fiscal year 2011: $17.77 million | Fiscal year 2011: $33.50 million | Fiscal year 2010: $26.08 million | Fiscal year 2009: $16.49 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026